Very interesting compilation.
This Q post is intriguing,
Why is Big Pharma essential?
Expand your thinking past cures.
Think Google [new Pixel phone].
Think Apple [vs. Samsung].
Why was Blackberry destroyed?
We can guide but you must organically uncover the TRUTH.
THEY are watching.
ARCHIVE EVERYTHING OFFLINE.
Q
I was looking at some interesting connections, the incredible wealth of Big Pharma today. Found this about the SECOND LARGEST flu vaccine manufacturer in the US.
Perreault and a handful of his top managers spent the best part of a year figuring out why the Novartis plant was doing so badly. It has required strong nerves. The losses knocked CSL’s net profit down to $US1.156 billion last year at the same time CSL took a bloody nose from shareholders who voted against Perreault’s $10 million compensation package.
“The culture change was, ‘Look. Here’s why we’re here. Let’s all get aligned on what the deliverables are. Let’s not get entertained with things that are interesting but will never see the light of day or are not going to deliver the seasonal flu vaccine,’” Perreault says.
“The first thing we have to do is get the seasonal flu out. That’s how we’re going to compete. Then we can think about the investments in some of the other areas and work with the government on some of these other projects.”
Management
The culture change necessitated management and staff changes at Seqirus. Some research staff left because they were pursuing non-flu projects that CSL wasn’t interested in.
The Holly Springs plant manager, who spent a year on the transition, left last year along with several key executives who reported to him. Perreault and Naylor brought in bioCSL general manager John Anderson and four other managers from CSL to run the plant while they worked on a plan to break even by 2018 and earn $US200 million trading profit by 2020. Some Novartis executives stayed in key leadership roles; a few were hired from outside.
The R&D spend is being wound back slowly as non-flu projects are completed. The focus is shifting to completing clinical trials of new vaccines that Seqirus needs to compete with rivals GlaxoSmithKline and Sanofi Pasteur, and improving the plant’s yield.
Like CSL’s core plasma business, successfully manufacturing flu vaccines requires high efficiency, low costs and large, commercial volumes. Unlike CSL’s other flu vaccines plants in Parkville and Liverpool, UK, Holly Springs manufactures vaccines from cells rather than eggs. It is a promising new process that is yet to reach optimum efficiency.
“They languished a bit trying to get those yields because they had these other projects going on. And we said, ‘OK, you need to focus on finishing clinical trials on flu and yield improvement,’” Perreault says.
Read more: http://www.afr.com/news/the-laser-focus-of-csls-paul-perreault-20170418-gvmxmo#ixzz589RjPrLO
Follow us: @FinancialReview on Twitter | financialreview on Facebook
Very interesting info, thank you.
And what struck me, is that Novartis is also the producer and pusher of Ritalin, which I blame for playing a major part in most of the mass shootings, especially the school shootings of recent decades.